{"groups":[{"description":"Participants harboring tumors with specific HER2 activating mutations received T-DXd 5.4 milligram/kilogram (mg/kg) via intravenous (IV) infusion on Day 1 of each cycle (21 days), every 3 weeks until response evaluation criteria in solid tumors (RECIST) version (v) 1.1 -defined PD, withdrawal of consent, or until any other of the discontinuation criteria was met.","id":"FG000","title":"Trastuzumab Deruxtecan (T-DXd)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"55"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"102"}],"comment":"Participants assigned to treatment and received treatment","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"33"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"69"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The study consisted of a screening period (up to 28 days), treatment period until progressive disease (PD) and a follow-up period for participants who discontinued study treatment due to PD or other reason. A total of 102 participants received treatment in this study.","recruitmentDetails":"This Phase II multicenter, open-label study was conducted in participants with unresectable and/or metastatic solid tumors harboring human epidermal growth factor receptor 2 (HER2) activating mutations regardless of tumor histology at 29 investigational sites in 9 countries. First participant was enrolled on 30 Dec 2020, last participant was enrolled on 24 May 2022 and data cut-off (DCO) date was 25 Jan 2023."}